RLX:NYSERLX Technology Inc. Analysis
Data as of 2026-06-12 - not real-time
$2.04
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Revenue momentum is the headline, with the latest quarter delivering almost double year‑over‑year sales and a noticeable lift in gross margin, driven largely by expanding international operations that now dominate the top line. Fundamentally, the company appears dramatically undervalued – the discounted cash‑flow estimate is many times the current market price, while the dividend yield is attractive but the payout ratio exceeds one hundred percent and free cash flow is negative, raising sustainability concerns.
Technical outlook is mixed: the stock trades below both the short‑term and intermediate simple moving averages, the MACD line sits just under its signal line, and the RSI hovers around the midpoint, suggesting limited upward bias. Volatility is elevated, beta is modest, and recent volume trends are weakening, with price perched near a key support level and facing a modest resistance ceiling.
Technical outlook is mixed: the stock trades below both the short‑term and intermediate simple moving averages, the MACD line sits just under its signal line, and the RSI hovers around the midpoint, suggesting limited upward bias. Volatility is elevated, beta is modest, and recent volume trends are weakening, with price perched near a key support level and facing a modest resistance ceiling.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 7/10
Key Factors
- price below short‑term moving averages
- bearish MACD divergence
- proximity to near‑term support
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- robust revenue growth and margin expansion
- significant valuation gap to DCF fair value
- potential for dividend policy adjustment as cash flow improves
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- sustained international market penetration
- defensive consumer sector positioning
- long‑term upside from deep undervaluation
Key Metrics & Analysis
Financial Health
Revenue Growth107.40%
Profit Margin22.47%
P/E Ratio18.5
ROE6.24%
ROA1.79%
Debt/Equity1.32
P/B Ratio1.1
Op. Cash Flow$828.5M
Free Cash Flow$-280764512
Technical Analysis
TrendBearish
RSI46.4
Support$1.96
Resistance$2.23
MA 20$2.06
MA 50$2.12
MA 200$2.32
MACDBearish
VolumeDecreasing
Fear & Greed Index87.59
Valuation
Fair Value$24.53
Target Price$2.99
Upside/Downside46.62%
GradeUndervalued
TypeBlend
Dividend Yield4.90%
Risk Assessment
Beta0.58
Volatility31.32%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.